StockNews.com started coverage on shares of iBio (NYSE:IBIO – Free Report) in a report published on Saturday. The firm issued a sell rating on the stock.
iBio Trading Up 4.1 %
Shares of IBIO opened at $1.79 on Friday. iBio has a fifty-two week low of $1.02 and a fifty-two week high of $26.20. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.04.
iBio (NYSE:IBIO – Get Free Report) last announced its quarterly earnings results on Friday, February 9th. The company reported ($2.42) earnings per share for the quarter.
iBio Company Profile
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
Further Reading
- Five stocks we like better than iBio
- 3 Stocks to Consider Buying in October
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- Most active stocks: Dollar volume vs share volume
- Merger or Not, Albertson’s Companies is a Good Buy
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
